Filing Details

Accession Number:
0001104659-16-153349
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-10-31 16:51:59
Reporting Period:
2016-10-31
Filing Date:
2016-10-31
Accepted Time:
2016-10-31 16:51:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1481512 Ra Pharmaceuticals Inc. RARX () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1439101 Morgenthaler Venture Partners Ix Lp 3200 Alpine Road
Portola Valley CA 94028
No No Yes No
1666860 Morgenthaler Management Partners Ix, Llc 3200 Alpine Road
Portola Valley CA 94028
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-10-31 63,019 $0.07 80,161 No 4 X Direct
Common Stock Disposition 2016-10-31 340 $13.00 79,821 No 4 S Direct
Common Stock Acquisiton 2016-10-31 1,392,130 $0.00 1,471,951 No 4 C Direct
Common Stock Acquisiton 2016-10-31 523,438 $0.00 1,995,389 No 4 C Direct
Common Stock Acquisiton 2016-10-31 486,919 $0.00 2,482,308 No 4 C Direct
Common Stock Acquisiton 2016-10-31 263,538 $13.00 2,745,846 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 X Direct
No 4 S Direct
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrants to Purchase Common Stock Disposition 2016-10-31 63,019 $0.00 63,019 $0.07
Common Stock Series A Preferred Stock Disposition 2016-10-31 9,744,916 $0.00 1,392,130 $0.00
Common Stock Series B-1 Preferred Stock Disposition 2016-10-31 3,664,071 $0.00 523,438 $0.00
Common Stock Series B-2 Preferred Stock Disposition 2016-10-31 3,408,439 $0.00 486,919 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2022-04-01 No 4 X Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. MMP IX disclaims beneficial ownership of the securities held by MVP IX except to the extent of its pecuniary interest therein.
  2. The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares.
  3. Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.
  4. Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.
  5. Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.